Royalty Pharma PLC $RPRX Shares Sold by Swedbank AB

Swedbank AB lessened its position in Royalty Pharma PLC (NASDAQ:RPRX) by 2.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,942,143 shares of the biopharmaceutical company’s stock after selling 258,127 shares during the period. Swedbank AB’s holdings in Royalty Pharma were worth $461,444,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Private Trust Co. NA grew its position in Royalty Pharma by 52.9% in the 4th quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 288 shares in the last quarter. Smartleaf Asset Management LLC grew its position in Royalty Pharma by 868.1% in the 3rd quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 790 shares in the last quarter. Larson Financial Group LLC grew its position in Royalty Pharma by 31.9% in the 3rd quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 306 shares in the last quarter. Richardson Financial Services Inc. bought a new position in Royalty Pharma in the 3rd quarter valued at about $54,000. Finally, Farther Finance Advisors LLC grew its position in Royalty Pharma by 44.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,060 shares of the biopharmaceutical company’s stock valued at $73,000 after buying an additional 632 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Stock Performance

Shares of RPRX opened at $50.44 on Wednesday. Royalty Pharma PLC has a one year low of $31.97 and a one year high of $50.82. The company has a 50-day moving average of $47.42 and a two-hundred day moving average of $42.56. The stock has a market cap of $29.10 billion, a price-to-earnings ratio of 37.36, a PEG ratio of 3.21 and a beta of 0.40. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.40 and a quick ratio of 2.40.

Royalty Pharma (NASDAQ:RPRX) last announced its earnings results on Wednesday, February 11th. The biopharmaceutical company reported $1.46 EPS for the quarter, topping the consensus estimate of $1.33 by $0.13. Royalty Pharma had a net margin of 32.38% and a return on equity of 28.21%. The company had revenue of $621.99 million during the quarter, compared to analysts’ expectations of $839.97 million. On average, equities research analysts expect that Royalty Pharma PLC will post 5.08 earnings per share for the current year.

Royalty Pharma Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be issued a $0.235 dividend. This represents a $0.94 annualized dividend and a dividend yield of 1.9%. The ex-dividend date is Friday, May 15th. Royalty Pharma’s dividend payout ratio (DPR) is presently 69.63%.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. The Goldman Sachs Group reiterated a “buy” rating on shares of Royalty Pharma in a research report on Thursday, February 12th. Wall Street Zen lowered shares of Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 14th. TD Cowen reiterated a “buy” rating on shares of Royalty Pharma in a research report on Friday, February 27th. Citigroup raised their price objective on shares of Royalty Pharma from $48.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, January 27th. Finally, UBS Group raised their price objective on shares of Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a research report on Tuesday, April 21st. Six analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Royalty Pharma has a consensus rating of “Buy” and a consensus price target of $50.33.

Insider Activity at Royalty Pharma

In other Royalty Pharma news, CFO Terrance P. Coyne sold 34,791 shares of the firm’s stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $49.78, for a total value of $1,731,895.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 139,164 shares of company stock valued at $6,624,902 in the last ninety days. Company insiders own 18.84% of the company’s stock.

Royalty Pharma Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.